click below
click below
Normal Size Small Size show me how
Endocrine 1
| Pharmacologic Category | Generic | Brand | Classification | Indications | Key Side effects | Other notes | US Boxed Warning |
|---|---|---|---|---|---|---|---|
| Biguanide | metformin (PO) | Fortamet, Glumetza | n/a | Type 2 DM, PCOS | Key Side Effects: diarrhea, nausea, vomiting, Vitamin B12 deficiency | Other Notes: CI with eGFR <30 | US Boxed Warnings: lactic acidosis |
| Dipeptidyl peptidase (DPP-4) inhibitor | sitagliptin (PO) | Januvia, Zituvio | n/a | Type 2 DM | Key Side Effects: nasopharyngitis | n/a | n/a |
| Sodium-glucose cotransporter inhibitor 2 (SGLT2 inhibitor) | empagliflozin (PO) | Jardiance | n/a | Type 2 DM, HF, CKD | Key Side Effects: genital mycotic infections, UTI | n/a | n/a |
| Sodium-glucose cotransporter inhibitor 2 (SGLT2 inhibitor) | dapagliflozin (PO) | Farxiga | n/a | Type 2 DM, HF, CKD | Key Side Effects: genital mycotic infections, UTI | n/a | n/a |
| Sulfonylurea | glimepiride (PO) | Amaryl | n/a | Type 2 DM | Key Side Effects: hypoglycemia, weight gain | n/a | n/a |
| Sulfonylurea | glipizide (PO) | Glucotrol, Glucotrol XL | n/a | Type 2 DM | Key Side Effects: hypoglycemia, weight gain | n/a | n/a |
| Thiazolidinedione (TZD) | pioglitazone (PO) | Actos | n/a | Type 2 DM | Key Side Effects: peripheral edema, weight gain, upper respiratory tract infection; increased risk of fractures and bladder cancer | n/a | US Boxed Warnings: may exacerbate congestive heart failure and CI in NYHA Class III and IV |
| Glucagon-like peptide-1 (GLP-1) receptor agonist | dulaglutide (SQ) | Trulicity | n/a | Type 2 DM | Key Side Effects: nausea, vomiting, diarrhea, pancreatitis | n/a | US Boxed Warning: may increase risk of thyroid c-cell tumor |
| Glucagon-like peptide-1 (GLP-1) receptor agonist | liraglutide (SQ) | Victoza, Saxenda | n/a | Type 2 DM, chronic weight management | Key Side Effects: nausea, vomiting, diarrhea, constipation, pancreatitis | n/a | US Boxed Warning: may increase risk of thyroid c-cell tumor, CI in personal or family history of medullary thyroid cancer |
| Glucagon-like peptide-1 (GLP-1) receptor agonist | semaglutide (PO, SQ) | SQ: Ozempic, Wegovy PO: Rybelsus | n/a | Type 2 DM, chronic weight management | Key Side Effects: nausea, vomiting, diarrhea, constipation, pancreatitis | n/a | US Boxed Warning: may increase risk of thyroid c-cell tumor, CI in personal or family history of medullary thyroid cancer |
| Dual GLP-1 and glucose- dependent insulinotropic polypeptide (GIP) agonist | tirzepatide (SQ) | Mounjaro, Zepbound | n/a | Type 2 DM, chronic weight management | Key Side Effects: nausea, vomiting, diarrhea, constipation, increased heart rate, pancreatitis | n/a | US Boxed Warning: may increase risk of thyroid c-cell tumor |
| Insulin, long acting | insulin glargine (SQ) | Lantus, Toujeo, Basaglar | n/a | Type 1 DM, type 2 DM | Key Side Effects: hypoglycemia, weight gain | n/a | n/a |
| Insulin, intermediate acting | insulin NPH (SQ) | Humulin N, Novolin N | OTC | Type 1 DM, type 2 DM | Key Side Effects: hypoglycemia, weight gain | n/a | n/a |
| Insulin, rapid acting | insulin aspart (SQ) | Novolog | n/a | Type 1 DM, type 2 DM | Key Side Effects: hypoglycemia, weight gain | n/a | n/a |
| Insulin, rapid acting | insulin lispro (SQ) | Humalog | n/a | Type 1 DM, type 2 DM | Key Side Effects: hypoglycemia, weight gain | n/a | n/a |
| Insulin, short-acting | insulin regular (SQ, IV) | Humulin R, Novolin R | SQ: OTC | Type 1 DM, type 2 DM, DKA | Key Side Effects: hypoglycemia, weight gain | n/a | n/a |